Udvalget konkluderede, at fordelene ved Adenuric er større end risiciene ved behandling af urinsyregigt ved tilstande, hvor der allerede er forekommet urataflejringer.
The Committee decided that Adenuric’ s benefits are greater than its risks for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred.